天津天津武清区龙济男人怎么样(查天津武清区龙济医院男科) (今日更新中)

BEIJING, Sept. 23 (Xinhua) -- A defunct U.S. satellite is expected to crash down to Earth Friday, with nobody knowing where or when exactly it will hit. This was avoidable, a Chinese expert said Thursday.Pang Zhihao, a researcher from the Chinese Research Institute of Space Technology, told Xinhua that the crash could have been avoided had the satellite been put into a higher orbit, or manipulated to drop in the South Pacific when it had abundant fuel. It would pose no threat to Earth if these measures had been taken.NASA's tumbling, 5,900 kg Upper Atmosphere Research Satellite, or UARS, is the first of such man-made space vehicles that have been launched into outer space according to the agency's Mission to Planet Earth. The mission was launched in the 1990s.The mission is designed to provide data for better understanding Earth's upper atmosphere and the effects of natural and human interactions on the atmosphere.The satellite was deactivated in 2005 as it ran out of fuel and was left orbiting Earth like a big piece of space junk.There are other cases of defunct satellites. The European Space Agency said earlier its observation satellite ERS-2 has run out of fuel and is deorbiting. It would therefore also crash sooner or later.Pang said all countries which are operating space vehicles should take care of their own spacecrafts so that they won't pose any danger.The expert also said that the public need not worry too much.Pang said most spacecrafts will be incinerated upon re-entering Earth's atmosphere, and the debris will mostly likely fall into the ocean or hit an uninhabited area. In addition, a debris tracker is able to give a comparatively accurate prediction where the craft will fall about two hours before it hits Earth, giving residents, if there are any, time to evacuate.He added that there are several ways to minimize the threat of decommissioned spacecrafts, like putting them into higher orbits and crashing them into designated waters.Scientific progress would possibly bring about more ways of dealing with tumbling satellites. Scientists have already been trying to build spacecrafts with degradable materials so that they can self-destruct when re-entering Earth's atmosphere.

BEIJING, July 26 (Xinhuanet) -- The breast cancer is more deadly to black women than to whites, a new study found.This finding was published online Monday on the "Journal of Clinical Oncology" in the United States.The study was done by the City of Hope, a Comprehensive Cancer Center in Duarte, California.The researchers collected data from more than 4,500 U.S. women in the 35-64 age group who were diagnosed with breast cancer.With the passing of  more than eight years, the researchers found the black women have a three times death rate than white women, after taking obesity and other diseases into account."It’s been long known that breast cancer in African-American women is a far less common disease than in white women. But when it occurs, it seems to be more aggressive and harder to treat," said Dr. Lisa Carey of the University of North Carolina’s Lineberger Comprehensive Cancer Center.But why the situations varied by race, scientists are still exploring the answer.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

来源：资阳报